Japan vs Norway: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Japan
0.0%
in 2024
Norway
0.0%
in 2024
Japan rank
143rd
Norway rank
143rd
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Japan
- Norway
How they compare
Japan currently reports 0.0% against 0.0% in Norway, a difference of 0.0%.
Across all 10 years both countries report, Norway has been ahead every year.
Japan ranks 143rd and Norway ranks 143rd of 215 countries.
Norway has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Japan | Norway | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.0% | 0.1% | 0.1% | Norway |
| 2020s | 0.0% | 0.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Japan or Norway?
- Japan, at 0.0% against 0.0% in Norway as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Japan and Norway?
- 0.0%, with Japan ahead.
- How many years of comparable data are there for Japan and Norway?
- 10 years are reported by both, from 2015 to 2024.
- How do Japan and Norway rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Japan ranks 143rd and Norway ranks 143rd of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.